口服抗凝药与同时使用NSAID的结果:基于注册表的队列研究
Nelish Ardeshna1, Josh Errickson2, Xiaowen Kong3
1Division of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, Ill, United States.
The American journal of medicine
|June 27, 2025
概括
结合口服抗凝剂 (OAC) 与非类固醇抗炎药物 (NSAID) 在现实研究中没有增加出血风险. 结果如出血,血栓形成和死亡率在OAC单独治疗和OAC加NSAID之间是相似的.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 临床医学 临床医学
- 心血管研究研究心血管研究
背景情况:
- 同时使用口服抗凝剂 (OAC) 和非类固醇抗炎药物 (NSAID) 是普遍存在的.
- 有关OAC和NSAID联合治疗增加出血风险存在担忧.
研究的目的:
- 评估在接受OAC治疗的患者中同时使用NSAID的频率.
- 评估NSAID同时使用对OAC患者临床结果的影响.
主要方法:
- 一个多中心,基于注册表的队列研究,使用4:1的倾向得分匹配.
- 从2011年到2023年,OAC单疗 (1796名患者) 与OAC+NSAID治疗 (449名患者) 的比较.
- 包括对VTE或AF进行OAC的成年人;排除涉及特定的并发症和抗血小板使用.
主要成果:
- 在12,083名OAC患者中,3.7%接受了同时服用NSAIDs.
- 匹配组 (OAC vs. OAC+NSAIDs) 在出血率上没有显著差异 (25.1 vs. 24.3 每 100 个患者年).
- 在两组之间观察到类似的血栓形成率,医疗保健利用率和死亡率.
结论:
- 现实世界的数据表明,OAC单独治疗和OAC与同时服用NSAIDs的临床结果相似.
- 鉴于疼痛管理选择有限,需要进一步的前性研究来证实这些发现.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
921
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
921
Venous Thrombosis III: Interprofessional Care
27
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
27
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
653
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
653
Venous Thrombosis IV: Nursing Management
27
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
27
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
41
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
41


